Ligand Pharmaceuticals Incorporated

Informe acción NasdaqGM:LGND

Capitalización de mercado: US$2.3b

Ligand Pharmaceuticals Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Ligand Pharmaceuticals de 35.5% y 15% respectivamente, mientras que el BPA crecerá en un 33.4% al año.

Información clave

35.5%

Tasa de crecimiento de los beneficios

33.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals23.7%
Tasa de crecimiento de los ingresos15.0%
Rentabilidad financiera futuran/a
Cobertura de analistas

Good

Última actualización14 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies

Nov 24

Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings

Oct 31
Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Jul 29

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Jul 18
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Jun 29
Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

May 23
Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio

Apr 30

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Dec 19
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

Jun 14
Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

May 29
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

May 07
Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Jan 26
These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Oct 21
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Ligand Pharmaceuticals: Struggling Along

Sep 25

Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Aug 11
Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Jun 27
Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:LGND - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/202621599911684
12/31/202518363601376
12/31/20241633422847
9/30/2024152452577N/A
6/30/202413342-448N/A
3/31/202411896-1734N/A
12/31/202313154-450N/A
9/30/2023154219095N/A
6/30/20231804199108N/A
3/31/202320451104120N/A
12/31/2022196-5120138N/A
9/30/20221832395112N/A
6/30/20221882797112N/A
3/31/202222345110120N/A
12/31/2021242767179N/A
9/30/2021275684552N/A
6/30/2021252483744N/A
3/31/2021208394248N/A
12/31/202016475155N/A
9/30/2020143-164147N/A
6/30/2020126-252428N/A
3/31/2020110-61-60-58N/A
12/31/2019120629781-29N/A
9/30/201915359481211N/A
6/30/201917467784644N/A
3/31/2019239764980179N/A
12/31/2018251143183194N/A
9/30/2018242179198193N/A
6/30/2018230120N/A193N/A
3/31/201816853N/A130N/A
12/31/201714113N/A89N/A
9/30/201712916N/A78N/A
6/30/20171179N/A69N/A
3/31/2017109-3N/A69N/A
12/31/2016109-2N/A61N/A
9/30/2016927N/A56N/A
6/30/201688205N/A48N/A
3/31/201687235N/A47N/A
12/31/201572230N/A42N/A
9/30/201574231N/A38N/A
6/30/20157133N/A32N/A
3/31/20156311N/A26N/A
12/31/20146512N/A21N/A
9/30/2014567N/A22N/A
6/30/2014548N/A18N/A
3/31/20145310N/A21N/A
12/31/2013499N/A21N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (35.5% al año) de LGND es superior a la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que los beneficios (35.5% al año) de LGND crezcan más rápidamente que el mercado US (15.4% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de LGND crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (15% al año) de LGND crezcan más rápidamente que los del mercado US (8.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 15% al año) de LGND crezcan más despacio que 20% al año.


Previsiones de crecimiento de los beneficios por acción


Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de LGND se prevé que sea elevada dentro de 3 años.


Descubre empresas en crecimiento